LogiCare3PL Aids Soleno's VYKAT XR Launch Post-FDA Approval

In a significant development for those suffering from Prader-Willi syndrome (PWS), a new FDA-approved treatment is now available. Named VYKAT™ XR, this therapy is the first and only treatment specifically designed to address hyperphagia, a debilitating symptom associated with PWS that causes chronic and insatiable hunger. This breakthrough marks a pivotal moment for patients, offering new hope for those affected by this genetic disorder.

LogiCare3PL, a company known for its expertise in specialty pharmaceutical logistics, is facilitating the distribution of VYKAT™ XR. They are responsible for ensuring the product reaches the patients who need it through their advanced logistics platform. Christian Carrier, Director of Client Services at LogiCare3PL, emphasized the importance of their role, stating that managing the logistics for such an innovative therapy is a serious responsibility. He highlighted that VYKAT™ XR signifies more than just a medical product; it represents a tangible source of hope for the PWS community and their families.

The launch of VYKAT™ XR is a momentous occasion for individuals with PWS. For the first time, they have access to a treatment targeting the incessant hunger and related challenges posed by hyperphagia. The therapy's availability marks a new chapter in managing symptoms that have long affected the quality of life for those with Prader-Willi syndrome.

During the launch event, Soleno Therapeutics' team members were present to celebrate this milestone with the LogiCare3PL operations staff. The gathering underscored the emotional and practical significance of each shipment, aligning with the shared mission of both companies to prioritize patient-centered logistics. Kevin Kissling, Vice President and General Manager at LogiCare3PL, described the event as a breakthrough moment for families dealing with PWS. He expressed pride in collaborating with Soleno Therapeutics to ensure patients have timely access to this eagerly anticipated treatment.

LogiCare3PL is dedicated to providing customized logistics solutions that help their partners distribute transformative therapies quickly, safely, and compassionately. As a part of BioCare, the company specializes in managing the distribution of life-saving medications that require careful handling due to their time and temperature sensitivity. Based in Tempe, Arizona, LogiCare3PL is a trusted partner in the pharmaceutical logistics sector, known for its precision and reliability.

This new development represents a major advancement for the Prader-Willi syndrome community, offering a therapeutic option that addresses a fundamental aspect of the condition. By working closely with Soleno Therapeutics, LogiCare3PL is playing a crucial role in supporting the delivery of VYKAT™ XR, ensuring that it is accessible to those who will benefit from it the most. The launch of this treatment is a testament to the commitment of both companies to improve the lives of patients through innovative medical solutions and effective distribution strategies.